Faron Pharmaceuticals Oy (“Faron” or “the Company”) Faron Announces New Biomarker Data from Phase I/II BEXMAB Study at EHA2023 Hybrid Congress Bexmarilimab mode of action in AML/MDS supported with durable Clever-1 target engagement in bone marrow, with increases observed in T and NK cells…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.